CliffBio
biologic

Neulasta

pegfilgrastim

Loss of exclusivityJanuary 2014projected — 12-year biologic exclusivity estimate
CompanyAmgen →See this company's full patent-cliff portfolio

Drug detail

Brand nameNeulasta
Active ingredientpegfilgrastim
Strength6MG/0.6ML
Dosage formInjection
RouteSubcutaneous
ModalityBiologic
FDA approvalJanuary 2002
Marketing statusRx

More from Amgen

Source: FDA Purple Book, layered on the CliffBio company graph. Cliff dates are the projected — 12-year biologic exclusivity estimate; estimates are projections, not legal advice.

Neulasta patent cliff — loss of exclusivity January 2014 | CliffBio